ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1225

Self Reported Comorbidity Is Common in Early Inflammatory Arthritis and Associated with Poorer Function and Quality of Life and Greater Disease Activity: Results From the Canadian Early Arthritis Cohort

Carol A. Hitchon1, Gilles Boire2, Boulos Haraoui3, Edward Keystone4, Janet E. Pope5, Vivian P. Bykerk6 and Canadian Early Arthritis Cohort (CATCH) Investigators7, 1University of Manitoba, Winnipeg, MB, Canada, 2Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, 3Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 4University of Toronto, Toronto, ON, Canada, 5Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Toronto, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Comorbidity, Health Assessment Questionnaire, quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chronic comorbid medical conditions may contribute to poor outcomes in rheumatoid arthritis.  The extent of comorbidity, in particular cardiovascular disease (CVD), may  be related to the burden of inflammation and may influence initial treatment choice.  We report the association of baseline comorbidity with clinical disease activity, functional status and quality of life in early inflammatory arthritis (EIA) using data from the Canadian Early Arthritis Cohort (CATCH).

Methods: Subjects (n=779) with EIA of symptom duration 6-52 weeks, ≥ 2 effused joints or1 swollen MCP or PIP and ≥ 2 of: +RF, +CCP, morning stiffness > 45 minutes, response to NSAIDS, or painful MTP squeeze test report comorbid medical conditions at baseline, quality of life indices (SF12) annually, and functional status (HAQ), pain visual analogue scale, detailed arthritis clinical assessments and arthritis treatment at each visit. Although there is no formal treatment protocol, participating rheumatologists aim for minimal disease activity.  The influence of baseline comorbidity on outcomes while controlling for age and disease duration was tested by linear regression.  

Results:  Comorbidity was reported by 538 subjects (69%; median conditions 1 range 0-8).  Patients with vs without comorbidity were older (45 vs 54 years p<0.0001) and had higher baseline disease activity primarily due to ESR (37 vs 21 p<0.001) and CRP (14 vs 11 p<0.02).  Associations between CVD and higher DASCRP3v (4.42(1.3) vs 4.18(1.3) p=0.03) and worse HAQ (1.13(0.73) vs 0.94(0.71) p<0.001) at baseline were not significant after correcting for age. Baseline SF12 scores (all patients) were below population averages (Physical Composite Score (PCS) 37(11) and Mental Composite Score (MCS) 47(12)).  SF12 correlated with the number of comorbidities: PCS (-0.2 p<0.0001) ; MCS (-0.11 p=0.003).  All domain scores were significantly worse in patients with any comorbidity vs without.  Patients with CVD (vs without) (34 (10) vs 38 (11) p<0.0001) endocrine disease (diabetes, thyroid, dyslipidemia) (35(11) vs 38(11) p=0.001), GI or renal (stomach bowel, liver disease, hepatitis or renal; 35(11) vs 38(11) p=0.03) and respiratory (asthma, bronchitis) (p=0.005) had poorer PCS.  Patients with neurologic (migraine, parkinson, seizures) (44(12) vs 47(11) p=0.03), mental health (depression or other)(39 (11) vs 48 (39) p<0.0001) and GI or renal (43(12) vs 47(11) p=0.005) comorbidities were associated with poorer MCS. Patients with any baseline comorbidity had higher DASCRP3v scores (3.15 (8.1) vs 2.94 (9.1) p=0.004), worse functional status (HAQ 0.67 (0.54) vs 0.47 (0.46) p<0.0001), and more pain (3.6 (2) vs 3.2 (2.1) p=0.001), averaged over the first year, than those without baseline comorbidity. Renal or GI disease had worse DASCRP3v (p<0.001) over the first year. Baseline cardiovascular disease was not associated with poorer outcomes.  The number of comorbid conditions at baseline was inversely associated with one year PCS and MCS.

Conclusion: Patients with comorbid medical conditions have greater disease activity, poorer functional status and lower self reported quality of life over the first year of followup.  This observation has implications for treatment of early arthritis.


Disclosure:

C. A. Hitchon,
None;

G. Boire,
None;

B. Haraoui,
None;

E. Keystone,

Abbott Laboratories Amgen Inc, AstraZeneca Pharamceuticals LP, Bristol-Myers Squibb, Centocor Inc, F. Hoffmann-LaRoche Inc, Genzyme, Merck, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, UCB,

2,

Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb, Centocor Inc, F. Hoffman-LaRoche Inc, Genentech Inc, Merck, Nycomed, Pfizer Pharmaceuticals, UCB, Amgen, Janssen Inc,

5;

J. E. Pope,
None;

V. P. Bykerk,

Amgen, Pfizer, Roche, BMS, UCB, Janssen Biotech and Abbott,

2;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/self-reported-comorbidity-is-common-in-early-inflammatory-arthritis-and-associated-with-poorer-function-and-quality-of-life-and-greater-disease-activity-results-from-the-canadian-early-arthritis-coho/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology